Besides, these studies showing efficacy in the targeting of VEGF-A and VEGF receptor genes in models of neovascularization lead to potential treatments for retinal diseases in which the pathology is primarily VEGF-driven, e.g., age-related macular degeneration or diabetic retinopathy, which are not IRDs but rather multifactorial diseases in which progressive visual impairment occurs, or lesions such as macular edema and ischemic retinal vein occlusions. This evidence concerns the gene VEGFA and macular retinal edema.